Phase I oncology studies: Evidence that in the era of targeted therapies patients on lower doses do not fare worse

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1289-1297

  Jain, Rajul K ^a   Lee, J Jack ^c   Hong, David ^a   Markman, Maurie ^b   Gong, Jing ^a   Naing, Aung ^a   Wheler, Jennifer ^a   Kurzrock, Razelle ^a  

^a Department of Investigational Cancer Therapeutics ^*

^b Division of Cancer Medicine

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASMS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 76749161498     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2684     Document Type: Article

References (41)

1. American Society of Clinical Oncology. Critical role of phase I clinical trials in cancer treatment. J Clin Oncol 1997;15:853-9.
2. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 1991;9:115-22.
3. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000;18: 684-92.
4. Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res 2005;11:5342-6.
5. Daugherty CK. Ethical issues in the development of new agents. Invest New Drugs 1999;17:145-53.
6. Markman M. The needs of science vs the needs of patients: ethical concerns in cancer clinical trials. Cleve Clin J Med 2003;70:1008-9, pp. 13-4, 16.
7. Meropol NJ, Weinfurt KP, Burnett CB, et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol 2003;21: 2589-96.
8. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 1995;13:1062-72.
9. Markman M. Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'? Cleve Clin J Med 2002;69:368-9, pp. 75-6.
10. Angelos P. Ethical issues in cancer patient care. 2nd ed. Springer; 1999.
11. Chen EX, Tannock IF. Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. JAMA 2004;292:2150-1.
12. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993;85:1637-43.
13. Lipsett MB. On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA 1982;248:941-2.
14. Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 2006;24:2987-90.
15. Dunn S. Steve's strategic guide to phase I cancer clinical trials. 2004, cited; Available from: http://www.cancerguide.org/trials-phase1. html.
16. Skipper HE, Schabel FR, Wilcox WS. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964;35:1-111.
17. Pinkel D, Hernandez K, Borella L, et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 1971;27:247-56.
18. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988;6:1501-15.
19. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-5.
20. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J. The anticancer drugs. 2nd ed. Oxford University Press; 1994.
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
23. Jiang H, Fine JP. Survival analysis. Methods Mol Biol 2007;404: 303-18.
24. Wheler J, Tsimberidou AM, Hong D, et al. Survival of patients in a Phase 1 clinic: the M. D. Anderson Cancer Center Experience. Cancer 2009;115:1091-9.
25. Postel-Vinay S, Arkenau HT, Olmos D, et al. Clinical benefit in phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 2009;100:1373-8.
26. Koyfman SA, Agrawal M, Garrett-Mayer E, et al. Risks and benefits associated with novel phase 1 oncology trial designs. Cancer 2007; 110:1115-24.
27. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008;112:2341-51.
28. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986;46:4831-6.
29. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2'- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62.
30. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004;96:990-7.
31. Seymour L. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Curr Pharm Des 2002;8: 2279-84.
32. Hoekstra R, Verweij J, Eskens FA. Clinical trial design for target specific anticancer agents. Invest New Drugs 2003;21:243-50.
33. Sleijfer S, Wiemer E. Dose selection in phase I studies: why we should always go for the top. J Clin Oncol 2008;26:1576-8.
34. Haines IE. Dose selection in phase I studies: why we should always go for the most effective. J Clin Oncol 2008;26:3650-2, author reply 2-3.
35. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002;7:401-9.
36. Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004;10:4607-13.
37. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol 1990;1:175-81.
38. Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 1986;70:1105-15.
39. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352: 895-904.
40. Roberts TG, Jr., Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004;292:2130-40.
41. Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 2005;352:930-2.